mGluR1 Activator

Fasoracetam (NS105) is an orally active metabotropic glutamate receptor (mGluR) activator. Fasoracetam bidirectionally regulates adenylyl cyclase activity and cAMP levels by activating group I-III mGluRs, upregulating GABAB receptors, and enhancing cholinergic neurotransmission. Fasoracetam can be used in research on attention deficit hyperactivity disorder (ADHD), depression, dementia, Alzheimer's disease, and forebrain ischemia.

Quisqualic acid (L-Quisqualic acid), a natural analog of glutamate, is a potent and pan two subsets (iGluR and mGluR) of excitatory amino acid (EAA) agonist with an EC₅₀ of 45 nM and a K_i of 10 nM for mGluR1R. Quisqualic acid is isolated from the fruits of Quisqualis indica.

VU6004909 is a blood-brain barrier penetrated mGlu1 positive allosteric modulator (PAM), with the EC₅₀s of 25.7 nM and 31 nM for human mGlu1 and rat mGlu1, respectively. VU6004909 reduces dorsolateral striatal dopamine (DA) release in vivo and displays antipsychotic efficacy.

mGluR1 activator-1 is a stable Vitamin K (HY-B2172) analogue and a mGluR1 activator that can penetrate the blood-brain barrier. mGluR1 activator-1 exhibits strong transcriptional activation via steroid and xenobiotic receptor as well as retinoic acid receptor. mGluR1 activator-1 induces neuronal differentiation in mouse neural progenitor cells. mGluR1 activator-1 can be used for the study of neurodegenerative disease such as Alzheimer’s.

Fasoracetam (NS 105) Standard is the analytical standard of Fasoracetam (HY-107481). This product is intended for research and analytical applications. Fasoracetam (NS105) is an orally active metabotropic glutamate receptor (mGluR) activator. Fasoracetam bidirectionally regulates adenylyl cyclase activity and cAMP levels by activating group I-III mGluRs, upregulating GABAB receptors, and enhancing cholinergic neurotransmission. Fasoracetam can be used in research on attention deficit hyperactivity disorder (ADHD), depression, dementia, Alzheimer's disease, and forebrain ischemia.